MicroRNA Expression in Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus: Associations with Survival

Ewy A. Mathé(Howard Hughes Medical Institute), Giang Huong Nguyen(Howard Hughes Medical Institute), Elise D. Bowman(Howard Hughes Medical Institute), Yiqiang Zhao(Howard Hughes Medical Institute), Anuradha Budhu(Howard Hughes Medical Institute), Aaron J. Schetter(Howard Hughes Medical Institute), Rosemary Braun(Howard Hughes Medical Institute), Mark Reimers(Howard Hughes Medical Institute), Kensuke Kumamoto(Howard Hughes Medical Institute), Duncan Hughes(Howard Hughes Medical Institute), Nasser K. Altorki(Howard Hughes Medical Institute), Alan G. Casson(Howard Hughes Medical Institute), Chang–Gong Liu(Howard Hughes Medical Institute), Xin Wei Wang(Howard Hughes Medical Institute), Nozomu Yanaihara(Howard Hughes Medical Institute), Nobutoshi Hagiwara(Howard Hughes Medical Institute), Andrew J. Dannenberg(Howard Hughes Medical Institute), Masao Miyashita(Howard Hughes Medical Institute), Carlo M. Croce(Howard Hughes Medical Institute), Curtis C. Harris(Howard Hughes Medical Institute)
Clinical Cancer Research
September 29, 2009
Cited by 378Open Access
Full Text

Abstract

PURPOSE: The dismal outcome of esophageal cancer patients highlights the need for novel prognostic biomarkers, such as microRNAs (miRNA). Although recent studies have established the role of miRNAs in esophageal carcinoma, a comprehensive multicenter study investigating different histologic types, including squamous cell carcinoma (SCC) and adenocarcinoma with or without Barrett's, is still lacking. EXPERIMENTAL DESIGN: miRNA expression was measured in cancerous and adjacent noncancerous tissue pairs collected from 100 adenocarcinoma and 70 SCC patients enrolled at four clinical centers from the United States, Canada, and Japan. Microarray-based expression was measured in a subset of samples in two cohorts and was validated in all available samples. RESULTS: In adenocarcinoma patients, miR-21, miR-223, miR-192, and miR-194 expression was elevated, whereas miR-203 expression was reduced in cancerous compared with noncancerous tissue. In SCC patients, we found elevated miR-21 and reduced miR-375 expression levels in cancerous compared with noncancerous tissue. When comparing cancerous tissue expression between adenocarcinoma and SCC patients, miR-194 and miR-375 were elevated in adenocarcinoma patients. Significantly, elevated miR-21 expression in noncancerous tissue of SCC patients and reduced levels of miR-375 in cancerous tissue of adenocarcinoma patients with Barrett's were strongly associated with worse prognosis. Associations with prognosis were independent of tumor stage or nodal status, cohort type, and chemoradiation therapy. CONCLUSIONS: Our multicenter-based results highlight miRNAs involved in major histologic types of esophageal carcinoma and uncover significant associations with prognosis. Elucidating miRNAs relevant to esophageal carcinogenesis is potentially clinically useful for developing prognostic biomarkers and identifying novel drug targets and therapies.


Related Papers

No related papers found

Powered by citation graph analysis